RETATRUTIDE - 12mg
Retatrutide is based on a GIP-like backbone with targeted substitutions and modifications that improve stability, potency, and pharmacokinetics. It incorporates α-aminoisobutyric acid (Aib) at positions 2 and 20, α-methyl-leucine at position 13, a C-terminal amidation, and a Lysine(17) fatty diacid (C20) side chain for half-life extension.
A synthetic 39–amino acid peptide and the first triple agonist of the GLP-1, GIP, and glucagon receptors,
Retatrutide is based on a GIP-like backbone with targeted substitutions and modifications that improve stability, potency, and pharmacokinetics. It incorporates α-aminoisobutyric acid (Aib) at positions 2 and 20, α-methyl-leucine at position 13, a C-terminal amidation, and a Lysine(17) fatty diacid (C20) side chain for half-life extension.
Preclinical and clinical research has shown it to strongly influence body-weight reduction, glucose regulation, and energy expenditure, making it a leading investigational molecule in incretin pharmacology.
Titan research and immune system function
Obesity & Weight Management:
Used in models to investigate sustained body-weight reduction through combined incretin and glucagon signaling.
Glucose Regulation:
Studied for its effects on insulin secretion, glycemic balance, and β-cell response.Energy Expenditure:Explored for thermogenic activation and lipid oxidation via GCGR engagement.
Comparative Incretin Research:
Benchmark for evaluating dual vs. triple receptor agonism.
Titan research and immune system function
Triple Receptor Agonism
Uniquely engages GLP-1, GIP, and GCGR pathways simultaneously.
Metabolic Effects
Drives reductions in body weight, fasting glucose, HbA1c, triglycerides, and liver fat in research models.
Peptide Engineering
Incorporation of non-canonical amino acids (Aib, α-Me-Leu) and lipid conjugation improves DPP-4 resistance and extends duration.
(1) Jastreboff, A. M., et al. (2023) Triple–Hormone–Receptor Agonist Retatrutide in Adults with Obesity. → Reported an average of ~4.2% weight loss by week 4 at higher doses. [New England Journal of Medicine, 389, 1451–1462]
(2) Wharton, S., et al. (2023) GIP/GLP-1/Glucagon triple agonists and metabolic adaptation. → Found early onset of weight reduction starting within the first week of use.
(3) Lilly Clinical Trials Database (2023) → Indicates dose-proportional reduction in body weight and improved insulin sensitivity by week 4 in Phase 2.
The chart illustrates the weight loss effects of Retatrutide over a four-week period in human clinical data. At week 1, participants showed an estimated 0.8% reduction in body weight, indicating an early and modest effect. By week 2, the reduction nearly doubled to 1.9%, showing that continued administration leads to a steady, measurable progression.
By week 4, the estimated body weight reduction reached 4.2%, marking the most substantial improvement within the short study timeframe. This consistent upward trend highlights Retatrutide’s potential as a powerful investigational agent in obesity research, particularly for its role in driving sustained reductions in body weight.
Form:
Lyophilized Powder
Storage (unreconstituted):
- Store at 2–8 °C (refrigerated), protected from light.
- For long-term storage, keep at –20 °C.
- Avoid repeated freeze–thaw cycles.
Reconstitution:
- Reconstitute with sterile water for injection or 0.9% NaCl immediately prior to use. Use aseptic technique.
Storage (after reconstitution):
- Store at 2–8 °C.
- Use within 7–10 days.
- Discard any unused solution after this period.
- Handle under sterile conditions.
- Do not shake vigorously (may cause peptide denaturation).
- Inspect visually for particulate matter or discoloration before use.
Issued for quality verification of tested material.
Feedback highlighting proven outcomes and reliability.
